SCHEMBL6077310

SCHEMBL6077310

O=C(O)C1=C(O)C(=O)N(CCc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 8/20 0.56
PARP1 P09874 2/20 0.50
PARP2 Q9UGN5 2/20 0.50
HDAC6 Q9UBN7 2/20 0.43
TAAR1 Q96RJ0 1/20 0.43
ACHE P22303 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
MCHR1 Q99705 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079147 0.91 LIPG (0.54) LIPGPARP1PARP2HDAC6HDAC3
SCHEMBL6078575 0.88 LIPG (0.54) LIPGKMT2A
SCHEMBL6078875 0.87 LIPG (0.45) LIPGPARP1PARP2MEN1KMT2A
SCHEMBL6077604 0.87 LIPG (0.57) LIPGMCHR1MEN1KMT2A
SCHEMBL7212684 0.84 LIPG (0.54) LIPGPARP1HDAC6KMT2AL3MBTL1
SCHEMBL6077852 0.83 CA1 (0.50) LIPGMEN1KMT2A
SCHEMBL6078569 0.82 LIPG (0.60) LIPG
SCHEMBL6077832 0.82 LIPG (0.44) LIPGMEN1KMT2A
SCHEMBL30774081 0.81 TP53 (0.52) LIPGPARP1PARP2HTT
SCHEMBL11380044 0.80 PARP1 (0.48) LIPGPARP1PARP2HDAC6TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF LIPG 2895/4885PARP1 65/4885PARP2 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.